Tigecycline's Impact on Transaminases
Tigecycline, a glycylcycline antibiotic, elevates serum transaminase levels (ALT and AST) in a dose-dependent manner, primarily through direct hepatotoxicity. Clinical trials showed grade 3/4 elevations in up to 7-9% of patients at standard doses (100 mg loading, 50 mg BID maintenance), higher than comparators like vancomycin (2-3%). These rises are typically asymptomatic, reversible upon discontinuation, and occur within 1-2 weeks of starting therapy.[1][2]
Frequency and Severity in Studies
In phase 3 trials (e.g., for complicated skin/skin structure infections and intra-abdominal infections), transaminase elevations >3x upper limit of normal (ULN) affected 1-2% of patients, with >10x ULN rare (<1%). Risk increases with prolonged use (>14 days) or higher doses (e.g., 100 mg BID), where ALT/AST spikes reached 15-20% incidence. Liver enzyme abnormalities resolved in 70-90% of cases post-treatment, but fatalities from hepatic failure occurred in <0.5%, often in patients with comorbidities.[1][3]
Mechanism of Hepatotoxicity
Tigecycline inhibits mitochondrial protein synthesis, disrupting hepatocyte energy metabolism and inducing oxidative stress, which damages transaminase-producing cells. It also mildly inhibits bile salt export pump (BSEP), potentially causing cholestasis. Unlike other tetracyclines, tigecycline's biliary excretion (59% of dose) concentrates it in the liver, amplifying exposure.[2][4]
Risk Factors and Patient Monitoring
Elevations are more common in hepatic impairment (Child-Pugh B/C: dose-adjust to 25-50 mg BID), obesity, or concomitant hepatotoxins (e.g., acetaminophen). Guidelines recommend baseline LFTs, weekly monitoring during therapy, and discontinuation if ALT/AST >5x ULN with symptoms. No cross-hypersensitivity with other tetracyclines.[3][5]
Comparison to Other Antibiotics
Tigecycline's transaminase signal exceeds imipenem (3-5%), levofloxacin (2%), or linezolid (1-2%), but matches ertapenem. It's less hepatotoxic than older tetracyclines like doxycycline at equivalent durations.[1][2]
Sources
[1]: FDA Tigecycline Label
[2]: Tigecycline Product Information, EMA
[3]: Stein GE, et al. Clin Ther 2007;29:552-60
[4]: Meagher AK, et al. J Antimicrob Chemother 2005;55:550-5
[5]: IDSA Guidelines on Antibiotic Use (hepatic monitoring)